These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 24506973)
1. Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. Laitman Y; Simeonov M; Keinan-Boker L; Liphshitz I; Friedman E Genet Res (Camb); 2013 Dec; 95(6):174-7. PubMed ID: 24506973 [TBL] [Abstract][Full Text] [Related]
2. 10-year performance of four models of breast cancer risk: a validation study. Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262 [TBL] [Abstract][Full Text] [Related]
3. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172 [TBL] [Abstract][Full Text] [Related]
4. Accuracy of Risk Prediction Models for Breast Cancer and Kenan ES; Friger M; Shochat-Bigon D; Schayek H; Bernstein-Molho R; Friedman E Anticancer Res; 2018 Aug; 38(8):4557-4563. PubMed ID: 30061222 [TBL] [Abstract][Full Text] [Related]
5. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population. Ghoncheh M; Ziaee F; Karami M; Poorolajal J Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418 [TBL] [Abstract][Full Text] [Related]
6. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers? Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258 [TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Antoniou AC; Durocher F; Smith P; Simard J; Easton DF; Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652 [TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
10. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856 [TBL] [Abstract][Full Text] [Related]
11. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869 [TBL] [Abstract][Full Text] [Related]
12. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684 [TBL] [Abstract][Full Text] [Related]
13. Cancer incidence in Israeli Jewish survivors of World War II. Keinan-Boker L; Vin-Raviv N; Liphshitz I; Linn S; Barchana M J Natl Cancer Inst; 2009 Nov; 101(21):1489-500. PubMed ID: 19861305 [TBL] [Abstract][Full Text] [Related]
14. Breast cancer trends in Israeli Jewish and Arab women, 1996-2007. Keinan-Boker L; Baron-Epel O; Fishler Y; Liphshitz I; Barchana M; Dichtiar R; Goodman M Eur J Cancer Prev; 2013 Mar; 22(2):112-20. PubMed ID: 23361380 [TBL] [Abstract][Full Text] [Related]
15. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123 [TBL] [Abstract][Full Text] [Related]
17. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Laitman Y; Borsthein RT; Stoppa-Lyonnet D; Dagan E; Castera L; Goislard M; Gershoni-Baruch R; Goldberg H; Kaufman B; Ben-Baruch N; Zidan J; Maray T; Soussan-Gutman L; Friedman E Breast Cancer Res Treat; 2011 Jun; 127(2):489-95. PubMed ID: 20960228 [TBL] [Abstract][Full Text] [Related]
18. Germline mutations in RAD51C in Jewish high cancer risk families. Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857 [TBL] [Abstract][Full Text] [Related]
19. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region. Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938 [TBL] [Abstract][Full Text] [Related]
20. Differences in pathological and clinical features of breast cancer in Arab as compared to Jewish women in Northern Israel. Zidan J; Sikorsky N; Basher W; Sharabi A; Friedman E; Steiner M Int J Cancer; 2012 Aug; 131(4):924-9. PubMed ID: 21918975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]